Evidence map›Paper›PMID 27026382›Full record

ArticleScientific reports2016

Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.

Yuanyuan Qu, Rui Zhao, Hongkai Wang, Kun Chang, Xiaoqun Yang, Xiaoyan Zhou, Bo Dai, Yao Zhu, Guohai Shi, Hailiang Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The expression and significance of p4E-BP1/4E-BP1 in prostate cancer.Journal of clinical laboratory analysis · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2020
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Translation initiation factors and their relevance in cancer.Current opinion in genetics & development · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Rui ZhaoInstitute of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Hongkai WangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Kun ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaoqun YangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaoyan ZhouDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Guohai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two main signaling pathways, PI3K-AKT-mTOR and RAS-MAPK, are involved in transmitting the proliferative signals which play critical roles in human cancers. However, the functions of these pathways in Xp11.2 RCC remain undefined. This study aimed to explore the expression of mTOR and MAPK cascades in Xp11.2 RCC and to assess the prognostic significance of proteins evaluated. Immunohistochemistry was performed to evaluate the expression of 4EBP1, p-4EBP1, p-mTOR, p-S6K and p-MAPK in 36 adult Xp11.2 RCC patients who were confirmed by FISH assay. Cox regression models were used to evaluate the prognostic value of all covariates. Among 36 assessed patients, 14 (38.9%), 26 (72.2%), 16 (44.4%), 19 (52.8%), and 9 (25.0%) patients showed high expression of 4EBP1, p-4EBP1, p-mTOR, p-S6K, and p-MAPK, respectively. We noted that p-4EBP1 expression was significantly correlated with lymph node metastases (P = 0.027). Multivariate analysis showed that high p-4EBP1 expression was an independent adverse prognostic factor for both PFS (HR = 33.750, P = 0.017) and OS (HR = 56.111, P = 0.026). Our findings suggest that p-4EBP1 may serve as a funnel factor that converge the upstream proliferative oncogenic signals. Effective inhibition of the pathways responsible for 4E-BP1 phosphorylation might be a useful strategy to improve the outcome of Xp11.2 RCC patients.

Indexed as

Adaptor Proteins, Signal TransducingAdolescentAdultBiomarkers, TumorCarcinoma, Renal CellCell Cycle ProteinsChromosomes, Human, XDisease-Free SurvivalDisease ProgressionFemaleHumansKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedMultivariate AnalysisAdaptor Proteins, Signal TransducingBiomarkers, TumorCell Cycle ProteinsEIF4EBP1 protein, humanPhosphoproteins

Identifiers

PMID27026382
PMCPMC4812307
OpenAlexW2332379504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.